Logo image of RNAC

CARTESIAN THERAPEUTICS INC (RNAC) Stock Fundamental Analysis

NASDAQ:RNAC - Nasdaq - US8162123025 - Common Stock - Currency: USD

10.68  -0.78 (-6.81%)

After market: 10.68 0 (0%)

Fundamental Rating

3

RNAC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. While RNAC seems to be doing ok healthwise, there are quite some concerns on its profitability. RNAC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RNAC had negative earnings in the past year.
RNAC had a negative operating cash flow in the past year.
In the past 5 years RNAC reported 4 times negative net income.
RNAC had negative operating cash flow in 4 of the past 5 years.
RNAC Yearly Net Income VS EBIT VS OCF VS FCFRNAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

With an excellent Return On Assets value of -10.39%, RNAC belongs to the best of the industry, outperforming 84.05% of the companies in the same industry.
Industry RankSector Rank
ROA -10.39%
ROE N/A
ROIC N/A
ROA(3y)-22.83%
ROA(5y)-25.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RNAC Yearly ROA, ROE, ROICRNAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

RNAC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNAC Yearly Profit, Operating, Gross MarginsRNAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

4

2. Health

2.1 Basic Checks

RNAC does not have a ROIC to compare to the WACC, probably because it is not profitable.
RNAC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RNAC has more shares outstanding
There is no outstanding debt for RNAC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RNAC Yearly Shares OutstandingRNAC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
RNAC Yearly Total Debt VS Total AssetsRNAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -1.82, we must say that RNAC is in the distress zone and has some risk of bankruptcy.
RNAC has a Altman-Z score (-1.82) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.82
ROIC/WACCN/A
WACC8.93%
RNAC Yearly LT Debt VS Equity VS FCFRNAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

RNAC has a Current Ratio of 12.34. This indicates that RNAC is financially healthy and has no problem in meeting its short term obligations.
RNAC has a better Current ratio (12.34) than 83.51% of its industry peers.
A Quick Ratio of 12.34 indicates that RNAC has no problem at all paying its short term obligations.
RNAC's Quick ratio of 12.34 is amongst the best of the industry. RNAC outperforms 83.51% of its industry peers.
Industry RankSector Rank
Current Ratio 12.34
Quick Ratio 12.34
RNAC Yearly Current Assets VS Current LiabilitesRNAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

RNAC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.73%, which is quite impressive.
Looking at the last year, RNAC shows a very strong growth in Revenue. The Revenue has grown by 35.14%.
RNAC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.27% yearly.
EPS 1Y (TTM)88.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.52%
Revenue 1Y (TTM)35.14%
Revenue growth 3Y-22.95%
Revenue growth 5Y42.27%
Sales Q2Q%-81.16%

3.2 Future

RNAC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.36% yearly.
The Revenue is expected to grow by 43.07% on average over the next years. This is a very strong growth
EPS Next Y71.04%
EPS Next 2Y28.77%
EPS Next 3Y17.16%
EPS Next 5Y7.36%
Revenue Next Year-91.26%
Revenue Next 2Y-89.36%
Revenue Next 3Y-80.95%
Revenue Next 5Y43.07%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RNAC Yearly Revenue VS EstimatesRNAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
RNAC Yearly EPS VS EstimatesRNAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RNAC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNAC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNAC Price Earnings VS Forward Price EarningsRNAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNAC Per share dataRNAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

RNAC's earnings are expected to grow with 17.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.77%
EPS Next 3Y17.16%

More info and screens

0

5. Dividend

5.1 Amount

RNAC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARTESIAN THERAPEUTICS INC

NASDAQ:RNAC (6/27/2025, 8:00:02 PM)

After market: 10.68 0 (0%)

10.68

-0.78 (-6.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners25.72%
Inst Owner Change-0.04%
Ins Owners57.95%
Ins Owner Change1.21%
Market Cap277.15M
Analysts81.43
Price Target36.89 (245.41%)
Short Float %43.99%
Short Ratio27.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.61%
Min EPS beat(2)5.53%
Max EPS beat(2)27.7%
EPS beat(4)3
Avg EPS beat(4)35.75%
Min EPS beat(4)-39.88%
Max EPS beat(4)149.63%
EPS beat(8)4
Avg EPS beat(8)-125.36%
EPS beat(12)6
Avg EPS beat(12)-124.07%
EPS beat(16)9
Avg EPS beat(16)-63.62%
Revenue beat(2)1
Avg Revenue beat(2)5.01%
Min Revenue beat(2)-27.24%
Max Revenue beat(2)37.26%
Revenue beat(4)2
Avg Revenue beat(4)357.55%
Min Revenue beat(4)-79.3%
Max Revenue beat(4)1499.47%
Revenue beat(8)4
Avg Revenue beat(8)215.45%
Revenue beat(12)6
Avg Revenue beat(12)156.13%
Revenue beat(16)10
Avg Revenue beat(16)147.6%
PT rev (1m)-7.66%
PT rev (3m)-7.6%
EPS NQ rev (1m)-3.99%
EPS NQ rev (3m)-9.35%
EPS NY rev (1m)-3.15%
EPS NY rev (3m)-8.77%
Revenue NQ rev (1m)-1.82%
Revenue NQ rev (3m)-1.82%
Revenue NY rev (1m)-1.17%
Revenue NY rev (3m)-36.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.92
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.86
EYN/A
EPS(NY)-3.99
Fwd EYN/A
FCF(TTM)-1.56
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS1.35
BVpS-0.84
TBVpS-8.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.39%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.83%
ROA(5y)-25.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 450.38%
Cap/Sales 27.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.34
Quick Ratio 12.34
Altman-Z -1.82
F-Score6
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)302.59%
Cap/Depr(5y)221.09%
Cap/Sales(3y)8.41%
Cap/Sales(5y)6.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.52%
EPS Next Y71.04%
EPS Next 2Y28.77%
EPS Next 3Y17.16%
EPS Next 5Y7.36%
Revenue 1Y (TTM)35.14%
Revenue growth 3Y-22.95%
Revenue growth 5Y42.27%
Sales Q2Q%-81.16%
Revenue Next Year-91.26%
Revenue Next 2Y-89.36%
Revenue Next 3Y-80.95%
Revenue Next 5Y43.07%
EBIT growth 1Y44.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y-65.62%
EBIT Next 5Y-21.06%
FCF growth 1Y-37.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.18%
OCF growth 3YN/A
OCF growth 5YN/A